ClinicalTrials.govpublic full text
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
advanced or refractory leukemia, lymphoma, multiple myeloma, leukemia, lymphoma, multiple myeloma, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 853532
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.